Cardiovascular disease risk reduction with sleep apnea treatment

Girardin Jean-Louis, Clinton D. Brown, Ferdinand Zizi, Gbenga Ogedegbe, Carla Boutin-Foster, Joseph Gorga, Samy I. McFarlane

Research output: Contribution to journalReview articlepeer-review


Cardiovascular diseases are the leading cause of death among adults in developed countries. An increase in prevalent cardiovascular risk factors (e.g., obesity, hypertension and diabetes) has led to a concerted effort to raise awareness of the need to use evidence-based strategies to help patients at risk of developing cardiovascular disease and to reduce their likelihood of suffering a stroke. Sleep apnea has emerged as an important risk factor for the development of cardiovascular disease. Epidemiologic and clinical evidence has prompted the American Heart Association to issue a scientific statement describing the need to recognize sleep apnea as an important target for therapy in reducing cardiovascular disease risks. This article examines evidence supporting associations of sleep apnea with cardiovascular disease and considers evidence suggesting cardiovascular risk reductions through sleep apnea treatment. Perspectives on emerging therapeutic approaches and promising areas of clinical and experimental research are also discussed.

Original languageEnglish (US)
Pages (from-to)995-1005
Number of pages11
JournalExpert Review of Cardiovascular Therapy
Issue number7
StatePublished - Jul 2010


  • cardiovascular disease
  • diabetes
  • dyslipidemia
  • hypertension
  • obesity
  • sleep apnea

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiovascular disease risk reduction with sleep apnea treatment'. Together they form a unique fingerprint.

Cite this